Healthcare News

RIAD, Saudi-Arabien, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Das King Faisal Specialist Hospital and Research Centre (KFSH) hat die Wartezeit bis zum ersten freien Termin für eine Echokardiographie in...

RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial...

PRESSRELEASE 2026-10-23 Rättelse: Kallelse till extra bolagsstämma i Arcoma AB (publ) Arcoma AB (publ) offentliggjorde den 21 oktober kallelse till extra bolagsstämma att hållas den 25 november...

Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving...

With 63% of 106 peptide and nanobody drug conjugates still preclinical, WuXi AppTec outlines five design decisions that shape manufacturability.

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral...

Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reportingMedian relative dose intensity...

AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer...

Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated...

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in...